

Attached are the following documents or web addresses for documents to support our position on collecting information under the Pharmaceutical Development Study.

(1) Janets Woodcock's (deputy commissioner of the fda) presentation at FDA Science Board



01-11-16 jw.ppt  
(49 KB)

(2) Critical Path Initiative <http://www.fda.gov/oc/initiatives/criticalpath/>

(3) Report from Pharmaceutical CGMP for the 21st Century Initiative  
[http://www.fda.gov/cder/gmp/gmp2004/GMP\\_finalreport2004.htm](http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm)

(4) Presentations on quality by design



i60921-ACPS-QbE  
Nasr.ppt (190 ...)



uqbd.ppt (524 KB)



ikqbd.ppt (506 KB)

5) Federal Register Notice on CMC Pilot for QbD for new drugs



Federal  
egister.doc (46 KE)

(6) CTD guidance <http://www.fda.gov/cder/guidance/4539Q.htm>

(7) Guidance on process analytical technologies <http://www.fda.gov/cder/guidance/6419fnl.htm>